DekaBank Deutsche Girozentrale lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,300 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. […]
Equities analysts expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will report earnings per share (EPS) of $1.20 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $3.13. iTeos […]
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) released its earnings results on Thursday. The company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $1.02, reports. The firm had revenue of $152.52 million for the quarter, compared to the consensus estimate of $63.30 million. ITOS stock traded up $0.01 […]
Wall Street analysts forecast that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will post sales of $63.30 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest sales estimate coming in at $40.00 million and the highest estimate coming in at $78.10 million. The […]
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Research analysts at Piper Sandler decreased their Q1 2022 EPS estimates for iTeos Therapeutics in a research note issued on Wednesday, March 23rd. Piper Sandler analyst C. Raymond now anticipates that the company will post earnings per share of $0.57 for the quarter, down from their previous […]